NCT01964287View on ClinicalTrials.gov

First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 24, 2013

Primary Completion Date

December 22, 2016

Study Completion Date

December 30, 2020

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
DRUG

GEMBRAX

DRUG

FOLFIRINOX

Trial Locations (1)

34298

Institut regional du Cancer - Val d Aurelle, Montpellier

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

NCT01964287 - First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. | Biotech Hunter | Biotech Hunter